{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.13997","value":"6.7161"},{"groupId":"OG001","spread":"4.33309","value":"7.9830"}]}],"title":"MMAE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.08387","value":"0.0730"},{"groupId":"OG001","spread":"0.02037","value":"0.0335"}]}],"title":"C4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.07377","value":"0.0836"},{"groupId":"OG001","spread":"0.01767","value":"0.0301"}]}],"title":"C5"},{"categories":[{"measurements":[{"comment":"None of the participants had data above LLQ and as per the predefined protocol results were to be summarized only for observations above LLQ, hence, data was not reported.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"None of the participants had data above LLQ and as per the predefined protocol results were to be summarized only for observations above LLQ, hence, data was not reported.","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.56047","value":"0.4477"},{"groupId":"OG001","spread":"0.06044","value":"0.0910"}]}],"title":"C8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.05107","value":"0.0551"},{"groupId":"OG001","spread":"0.01738","value":"0.0345"}]}],"title":"C13"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Metabolites of MMAE includes C4, C5, C7, C8 and C13. Amount of MMAE and its metabolites in urine were determined by multiplying the volume of urine obtained and the concentration of MMAE and its metabolites present in it, respectively. The LLQ for determining the concentration was 0.01 ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses.","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Brentuximab vedotin 1.8 mg/kg, injection, intravenously, every 3 weeks on Day 1 of each 21-day treatment cycle up to a maximum of 16 brentuximab vedotin doses and rifampicin, 600 mg, capsules, orally, once daily from Day 1 of treatment Cycle 0 through Day 21 of treatment cycle 3.","id":"OG001","title":"Brentuximab Vedotin + Rifampicin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who received brentuximab vedotin at 1.8 mg/kg throughout Cycles 1 to 3 and had sufficient dosing and PK data to reliably estimate PK parameters.","reportingStatus":"POSTED","timeFrame":"Cycle 1: 120-144 hours postdose","title":"Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose","type":"PRIMARY","unitOfMeasure":"ng"}